263 related articles for article (PubMed ID: 34819035)
1. No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter.
Sabazade S; Herrspiegel C; Gill V; Stålhammar G
BMC Cancer; 2021 Nov; 21(1):1270. PubMed ID: 34819035
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas.
Isager P; Ehlers N; Overgaard J
Acta Ophthalmol Scand; 2004 Oct; 82(5):517-25. PubMed ID: 15453846
[TBL] [Abstract][Full Text] [Related]
3. Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome.
Marinkovic M; Horeweg N; Fiocco M; Peters FP; Sommers LW; Laman MS; Bleeker JC; Ketelaars M; Luyten GP; Creutzberg CL
Eur J Cancer; 2016 Nov; 68():106-113. PubMed ID: 27741435
[TBL] [Abstract][Full Text] [Related]
4. Small metastasizing choroidal melanomas.
Malclès A; Kivelä T; Svetlosakova Z; Jean-Louis B; Nguyen AM; Sallit R; Négrier S; Pommier P; Rivoire M; Chauvel P; Mammar H; Devouassoux-Shisheboran M; Kodjikian L; Denis P; Grange JD
Acta Ophthalmol; 2015 Mar; 93(2):e160-6. PubMed ID: 25124923
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm.
Filì M; Trocme E; Bergman L; See TRO; André H; Bartuma K; Girnita L; All-Eriksson C; Seregard S; Stålhammar G
Br J Ophthalmol; 2020 Jan; 104(1):26-32. PubMed ID: 30910871
[TBL] [Abstract][Full Text] [Related]
6. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays).
Rouberol F; Roy P; Kodjikian L; Gérard JP; Jean-Louis B; Grange JD
Am J Ophthalmol; 2004 May; 137(5):893-900. PubMed ID: 15126155
[TBL] [Abstract][Full Text] [Related]
7. [Ciliary body melanomas. Survival and prognostic aspects after brachytherapy or proton therapy].
Gambrelle J; Kodjikian L; Rouberol F; Donate D; Duquesne N; Jean-Louis B; Chauvel P; Gérard JP; Romestaing P; Grange JD
J Fr Ophtalmol; 2004 Jan; 27(1):40-7. PubMed ID: 14968076
[TBL] [Abstract][Full Text] [Related]
8. Transscleral resection versus iodine brachytherapy for choroidal malignant melanomas 6 millimeters or more in thickness: a matched case-control study.
Kivelä T; Puusaari I; Damato B
Ophthalmology; 2003 Nov; 110(11):2235-44. PubMed ID: 14597535
[TBL] [Abstract][Full Text] [Related]
9. [Survival rates for large choroidal melanomas].
Stoiukhina AS; Chesalin IP
Vestn Oftalmol; 2014; 130(4):39-44. PubMed ID: 25306722
[TBL] [Abstract][Full Text] [Related]
10. Long-term Outcomes After Proton Beam Irradiation in Patients With Large Choroidal Melanomas.
Papakostas TD; Lane AM; Morrison M; Gragoudas ES; Kim IK
JAMA Ophthalmol; 2017 Nov; 135(11):1191-1196. PubMed ID: 29049518
[TBL] [Abstract][Full Text] [Related]
11. Management of choroidal melanomas less than 10 mm in largest basal diameter with a 10-mm ruthenium plaque.
Salkola S; Heikkonen J; Eskelin S; Kivelä T
Retina; 2014 Oct; 34(10):2110-20. PubMed ID: 24978431
[TBL] [Abstract][Full Text] [Related]
12. Prognosis of choroidal melanoma and the result of ruthenium brachytherapy combined with transpupillary thermotherapy in Korean patients.
Kwon HJ; Ko JS; Kim M; Lee CS; Lee SC
Br J Ophthalmol; 2013 May; 97(5):653-8. PubMed ID: 23428983
[TBL] [Abstract][Full Text] [Related]
13. Survival after primary enucleation for choroidal melanoma: changes induced by the introduction of conservative therapies.
Gambrelle J; Grange JD; Devouassoux Shisheboran M; Rivoire M; Baggetto LG; Jean-Louis B; Fleury J; Kodjikian L
Graefes Arch Clin Exp Ophthalmol; 2007 May; 245(5):657-63. PubMed ID: 17119996
[TBL] [Abstract][Full Text] [Related]
14. Clinical Predictors of Regression of Choroidal Melanomas after Brachytherapy: A Growth Curve Model.
Rashid M; Heikkonen J; Singh AD; Kivelä TT
Ophthalmology; 2018 May; 125(5):747-754. PubMed ID: 29499831
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma.
Verschueren KM; Creutzberg CL; Schalij-Delfos NE; Ketelaars M; Klijsen FL; Haeseker BI; Ligtenberg SM; Keunen JE; Marijnen CA
Radiother Oncol; 2010 Jun; 95(3):332-8. PubMed ID: 20416963
[TBL] [Abstract][Full Text] [Related]
16. The melanoma controversy. A comparison of choroidal, cutaneous, and iris melanomas.
Davidorf FH
Surv Ophthalmol; 1981; 25(6):373-7. PubMed ID: 7245022
[TBL] [Abstract][Full Text] [Related]
17. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant proton beam irradiation vs. adjuvant ruthenium brachytherapy in transscleral resection of uveal melanoma.
Böker A; Pilger D; Cordini D; Seibel I; Riechardt AI; Joussen AM; Bechrakis NE
Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1767-1775. PubMed ID: 29907945
[TBL] [Abstract][Full Text] [Related]
19. Iris Melanoma Outcomes Based on the American Joint Committee on Cancer Classification (Eighth Edition) in 432 Patients.
Shields CL; Di Nicola M; Bekerman VP; Kaliki S; Alarcon C; Fulco E; Shields JA
Ophthalmology; 2018 Jun; 125(6):913-923. PubMed ID: 29342436
[TBL] [Abstract][Full Text] [Related]
20. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas.
Nag S; Quivey JM; Earle JD; Followill D; Fontanesi J; Finger PT;
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):544-55. PubMed ID: 12738332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
